EMA Authorised: Bondronat (ibandronic acid) — Atnahs Pharma Netherlands B.V.

View source ↗

Summary

EU marketing authorisation granted to Bondronat (ibandronic acid) for hypercalcemia, breast cancer with bone metastases, and bone-related fractures, held by Atn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Fractures
• Bone Metastases
• Breast Cancer
• Hypercalcemia

Drugs mentioned

• Bondronat (ibandronic acid)

Snippet

Status: Authorised. Therapeutic area: Hypercalcemia;Breast Neoplasms;Neoplasm Metastasis;Fractures, Bone. MAH: Atnahs Pharma Netherlands B.V.. Decision date: 25/01/2024